Newborn infections are a leading cause of infant deaths worldwide, exacerbated by the growing threat of antimicrobial resistance (AMR). In Kenya and across Africa, neonatal sepsis claims thousands of lives each year, often due to resistant bacteria. The NeoSep1 Trial, led by the Global Antibiotic Research & Development Partnership, is pioneering a new approach to optimize antibiotic treatment for newborns. By testing innovative drug combinations and tailored dosing regimens, this multi-country study aims to reshape newborn care and strengthen the global fight against AMR. Discover how this groundbreaking research is making a difference in the lives of vulnerable infants.

KEMRI-Wellcome recently participated in the 3rd Kilifi County Health Scientific Symposium, a pivotal event focused on “Sustaining Universal Health Coverage: Innovations, Research, and Best Practices.” This gathering united policymakers, researchers, and healthcare professionals to explore evidence-based solutions for enhancing health systems in Kilifi County and beyond. With engaging scientific presentations and dynamic panel discussions, the symposium showcased the vital role of research in shaping health policies. Discover how local data and collaborative efforts are driving progress towards universal health coverage and improving health outcomes for communities. Join us in exploring the future of health innovation!

The AMR Kenya 2026 Conference, held on 21–22 January 2026 at Serena Beach Resort & Spa in Mombasa, brought together experts, policymakers, funders, researchers, and community leaders to co-create practical, locally relevant solutions to antimicrobial resistance (AMR) in Kenya and across the region. Convened under the theme “Working Together to Tackle AMR in Kenya,” the conference addressed the […]